Older women with breast cancer are almost twice a likely to die or suffer a relapse if they are treated with Roche’s Xeloda rather than standard chemotherapy after surgery to remove the tumor, a study found.
The results show the choice of therapy is critical for women aged 65 and older with early-stage breast cancer, a group that is rarely included in clinical trials, said researchers led by Hyman Muss, professor of oncology at the University of Vermont in Burlington. Xeloda, from Basel, Switzerland-based Roche, is an oral form of chemotherapy that generated 1.2 billion Swiss francs ($1.1 billion) in 2008.
More at Bloomberg
No comments:
Post a Comment